Swim expert offers safety tips ahead of Memorial Day Weekend
MADISON, Ala. (WHNT) — Memorial Day Weekend is well-known as the kick-off to summer. Many neighborhood pools and waterparks start to open for the season this time of year.
However, a fun afternoon at the pool can turn dangerous in a split second.
Gold Star families honored on Redstone Arsenal
According to the American Academy of Pediatrics, drowning is the number one cause of injury death for children ages one to four in the U.S. Unfortunately, there were several child drowning reports in North Alabama in 2024.
'Drowning, unfortunately, is usually very quiet, and it happens really quickly,' said Kylie Beckwith, the Deck Supervisor at Goldfish Swim School in Madison. She said, unlike in the movies, the person isn't usually flailing their arms and shouting for help.
That's why she says it's so important to teach your children about water safety and to teach them water survivor skills.
Beckwith said, knowing where to go to get safe is the biggest thing.
'So making sure they're learning to turn to their back to get safe so that they can get air and parents can see or other grown-ups can see them, that they're in distress or calling for help,' Beckwith said.
Starstruck: The original Huntsville Mr. Baseball, Don Mincher
As a new mom herself, Beckwith recommends getting your child in swim lessons starting as an infant. Goldfish Swim School starts lessons for babies at four months old.
'The importance of starting them young, and I do it for my daughter as well, is just getting exposure to the pool, other kids, how to interact with other children in the water,' Beckwith told News 19.
Besides talking to your kids about having boundaries near bodies of water, she recommends putting extra protections in place if you have a backyard pool.
'Please make sure there's a gate around your pool,' she said. 'That it's always closed, locked, whatever you need to do.'
Regardless of how strong of a swimmer that your child is, she also recommends having them wear a U.S. Coast Guard approved life jacket.
She said the color of their swimsuit can also help them be seen in a pool, and a potential emergency.
📲 to stay updated on the go. 📧 to have news sent to your inbox.
'As cute as some of the light blues, the neutral colors that are really popular right now, as great as those things are, they blend in really easily with the pool,' Beckwith said. 'So if a parent is scanning or a lifeguard is scanning, it does make it a little bit more difficult to see them.'
If you're swimming somewhere without a lifeguard on duty, she reminds parents to pay attention at all times and not get distracted by things like cell phones.
'Just keeping eyes on the pool, making sure you don't walk away without communicating with someone to have eyes on them too,' she said.
She said to never assume another parent is watching the pool and that it's good to designate a pool watcher.
Goldfish Swim School offers a wide range of classes and swim lessons for different age groups. The YMCA also offers swim lessons.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
21 minutes ago
- Medscape
Which Tx Combo Is Best for HER2+ Breast Cancer?
The combination of trastuzumab deruxtecan (Enhertu) with pertuzumab (Perjeta) as a first-line treatment for HER2-positive advanced metastatic breast cancer has been shown to reduce the risk for disease progression or death by more than the current standard-of-care treatment. Sara Tolaney, MD, MPH Sara Tolaney, MD, MPH, of the Dana-Farber Cancer Institute in Boston, presented this finding and other interim results of the phase 3 DESTINY-Breast09 study, at the American Society of Clinical Oncology (ASCO) 2025 annual meeting in Chicago. 'Trastuzumab deruxtecan, or T-DXd, in combination with pertuzumab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival, with a 44% reduction in the risk of disease progression or death when compared to a taxane, trastuzumab, and pertuzumab (THP),' said Tolaney, during her presentation. New First-line Standard? Similar results were observed across all patient subgroups, with no new safety signals, Tolaney said. 'These data suggest that T-DXd and pertuzumab may represent a new first-line standard of care for patients with metastatic HER2-positive breast cancer,' she said. The study randomized 1157 patients to three treatment groups: T-DXd 5.4 mg/kg every three weeks plus placebo, T-DXd-pertuzumab, or a taxane plus trastuzumab with pertuzumab (THP). The interim study readout includes only data from the T-DXd-pertuzumab and the taxane plus trastuzumab with pertuzumab groups. Pertuzumab + T-Dxd or Standard of Care? Median progression-free survival (PFS) was 40.7 months in the T-DXd-pertuzumab patients and 26.9 months in the taxane plus trastuzumab with pertuzumab patients ( P < .00001). Tolaney explained that the study was designed to have an interim analysis for PFS after approximately 399 events across the three arms with at least 277 events for comparison. At the time of the interim analysis, she said, only the TDX-pertuzumab and THP groups met the criteria for superiority, a P -value < .00043, which was not met for the comparison of T-DXd plus placebo to THP. The T-DXd-placebo arm remains blinded until the final progression-free survival analysis, Tolaney said. Twenty-one percent of the patients in the T-DXd-pertuzumab arm had discontinued T-DXd due to adverse events, Tolaney said; 9% of patients elected to continue with trastuzumab and pertuzumab after they discontinued T-DXd. Among hormone receptor-positive patients, 13.5% in the T-DXd-pertuzumab group and 38% in the THP group elected to add endocrine treatment. At the data cutoff, 46% of the T-DXd-pertuzumab patients and 33% of those in the THP group remained on study treatment. Median follow-up duration was 29 months. The treatment effect of T-DXd-pertuzumab became evident early in the study, Tolaney said. Six months after starting treatment, 7% of the T-DXd-pertuzumab group vs 12% of the THP group had progressed. The gap continued to widen over time, she said. 'With 26% of patients still on steady treatment with T-DXd and pertuzumab, it suggests that this median is likely to evolve with further follow-up,' she said. Objective response rates were also higher with T-DXd–pertuzumab, 86% vs 79% with THP, Tolaney said. 'The complete response rate for T-DXd and pertuzumab was 15%, which was almost double what was seen with THP (8.5%),' she said. Response duration was also longer with T-DXd-pertuzumab, with 73% remaining in response at 24 months vs 55% in the THP arm. 'Overall survival data are very immature at this timepoint with just 16% of survival events seen, but you can see that there is an early trend favoring T-DXd plus pertuzumab with a hazard ratio of 0.84,' she said. A similar number of patients in both groups had serious treatment-emergent adverse events: 27% for T-DXd-pertuzumab and 25.1% for THP, which Tolaney said, was consistent with the known toxicity profiles of both agents, with no new toxicities identified. The median duration of treatment in the DESTINY-Breast09 study was 21 months. 'A Pivotal Advancement?' Rebecca Dent, MD, deputy CEO at the National Cancer Center Singapore, called the DESTINY-Breast09 results 'a pivotal advancement in the treatment of HER2-positive metastatic breast cancer that is both clinically and statistically significant.' Rebecca Dent, MD HER2-positive metastatic breast cancer was once considered a 'death sentence,' Dent said at a press conference, but now patients can survive on therapy for years, which presents its own challenges. Regarding the T-DXd-plus-pertuzumab regimen, Dent said, 'Is this for all patients at the beginning of their treatment for metastatic disease?' The truth of the matter is we don't know.' Having better biomarkers would provide answers, she said, but for patients with extensive disease with central nervous system metastasis, pertuzumab in combination with other agents 'is clearly your first-line choice.' How to best sequence therapies is another challenge emerging with these evolving treatment regimens, Dent added. 'And then I think finally we do have to appreciate that there are toxicities: One in terms of quality of life but also cost toxicity,' she said. Which Therapeutic Regimen Costs More? Tolaney acknowledged the cost implications of adding pertuzumab to T-DXd, in an interview with Medscape Medical News . 'But I would also note,' Tolaney said, 'that the standard-of-care arm does involve getting continued trastuzumab and pertuzumab therapy.' In the PATINA study, which added palbociclib (Ibrance) to standard maintenance therapy in patients with HER2-positive metastatic breast cancer, the cost profile was similar to those of the treatments used in the newer trial, Tolaney said. 'You are looking at substantial continued cost because we're continuing to suppress the HER2 pathway for years in these patients,' she said. AstraZeneca and Daiichi Sankyo funded the study. Tolaney reported financial relationships with ADi, Ambrx, Artios Biopharmaceuticals, Arvinas, AstraZeneca, Bayer, BeiGene, Bicycle Therapeutics, BioNTech, Blueprint Medicines, Bristol Myers Squibb, Circle Pharma, Cullinan Oncology, Daiichi Sankyo, eFFECTOR Therapeutics, Eisai, Exelixis, Genentech, Gilead Sciences, Hengrui Pharmaceutical (USA), Immunomedics/Gilead, Incyte, Jazz Pharmaceuticals, Johnson & Johnson, Launch Therapeutics, Lilly, Menarini Group, Merck, Mersana, NanoString Technologies, Natera, Novartis, OncoPep, Pfizer, Reveal Genomics, Sanofi, Seagen, Sumitovant Biopharma, Summit Therapeutics, Systimmune, Tango Therapeutics, Zentalis, Zuellig Pharma, and Zymeworks. Dent reported having financial relationships with AstraZeneca, Daiichi Sankyo/Astra Zeneca, DKSH, Eisai, Gilead Sciences, Merck Sharpe and Dohme, Novartis, Pfizer, and Roche.
Medscape
35 minutes ago
- Medscape
Medscape at 30: Three Decades of Big Events in Medicine
Medscape turns 30 in 2025. To mark this milestone, the Medscape 2050 project looks at what the field of medicine may look like 25 years from now. But the future is also shaped by the past. Below we look at the previous 30 years through the lens of Medscape News' coverage of the headlines and events that helped define medicine since 1995. May 22, 1995: Medscape Launches Remember what the early days of the internet were like? That's Medscape, launched out of a tiny office in Manhattan on May 22, 1995, by a scrappy group of people who had a great idea for a website to serve a physician readership. Here's what those early days were like. 1996: Highly Active Antiretroviral Therapy (HAART) Revolutionizes HIV/AIDS Treatment John G. Bartlett, MD, offers a thorough breakdown of HAART's evolution, with notable mention of a certain director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health (NIH), Anthony Fauci. Ten years after this breakthrough, Medscape continued in-depth coverage, including this long Q&A with Richard Elion, MD. March 27, 1998: Viagra Approved by the FDA The first oral treatment for erectile dysfunction became a cultural phenomenon and, from a news perspective, the gift that kept on giving, leading to ongoing coverage not just in the ensuing years but for decades — including evidence 26 years later that the little blue pill may help prevent Alzheimer's. 1999: Vioxx and COX-2 Inhibitors Introduced The arrival of the new class of painkillers was less newsworthy than what followed later, with Vioxx linked to heart risks and pulled from the market. The fallout brought harsh questions about its initial FDA approval. March 2003: SARS Outbreak The global epidemic led to the first modern pandemic response, and just like the pandemic that would follow 17 years later, it spurred ongoing Medscape coverage that may seem quaint in retrospect. May 2005: Medscape Celebrates 10 Years Our 10th anniversary brought a comprehensive reckoning of some of the major medical advances from 1995 to 2004, including analysis of impactful stories across all specialties. November 24-25, 2005: First Successful Face Transplant Performed A new day for reconstructive surgery when surgeons grafted the donor nose, lips, and chin to the face of a 38-year-old French woman whose lips and nose were ripped off in a dog attack. The breakthrough procedure led to a sharp debate about whether the surgery should have happened at all. 2009: H1N1 (Swine Flu) Pandemic Six years after SARS, H1N1 gave us the first official flu pandemic in decades, prompting massive vaccine production, as well as inevitable comparisons to the 1918 pandemic, with the two strains, separated by 91 years, sharing similar features. March 23, 2010: Affordable Care Act (ACA) Signed Into Law in the US President Obama's signature legislation was a seismic health policy shift increasing insurance access. The law has been scrutinized (and challenged) ever since. Meanwhile, more than 24 million people signed up for ACA Marketplace Coverage for 2025, a new record. 2013: Angelina Jolie's BRCA1 Op-ed Spurs Genetic Testing Boom Celebrities can single-handedly transform public discourse on health issues, and Jolie did just that with hereditary cancer risk. As a result of the 'Angelina Jolie Effect,' BRCA testing doubled. 2014: Ebola Outbreak in West Africa While the outbreak highlighted weaknesses in global public health infrastructure, Medscape highlighted what US clinicians needed to know — as well as what they didn't know. In September, the WHO convened a 2-day meeting in Geneva to discuss therapies derived from survivors' blood. October 26, 2019: US Declares Opioid Epidemic a National Health Emergency Addiction treatment, regulation, and pharmaceutical accountability all became part of public medical discourse as part of the outcry to declare a state of emergency on opioids. President Trump eventually declared the crisis a national public health emergency. In 2019, opioid-related deaths reached almost 72,000, a new high. Death rates continued to rise well into 2020. 2019: Measles Outbreaks Reemerge Due to Vaccine Hesitancy A global spike in cases, especially in the US and Europe, foreshadowed measles news in 2025, but physicians were just as concerned then about the measles and vaccine hesitancy. 2020: COVID-19 Global Pandemic Declared Perhaps the biggest medical news event in Medscape's history, and as you can see, this selection of six headlines offers a telling timeline of just what was going on — what we knew and a whole lot we didn't…. March 11, 2020, WHO declares COVID-19 a pandemic So You Have a COVID-19 Patient; How Do You Treat Them? COVID-19: Time to 'Take the Risk of Scaring People' A Decade of Telemedicine Policy Has Advanced in Just 2 Weeks Year of COVID: Everything We Thought We Knew Was Wrong 'Death by 1000 Cuts': Medscape National Physician Burnout & Suicide Report 2021 June 24, 2022: US Overturns Roe v. Wade (Dobbs Decision) One of the most impactful legal decisions in US history with major implications for reproductive healthcare. Aside from the news itself, the decision spurred Medscape coverage on both sides of the issue in the medical world. Ob/Gyns on the Day That Roe v. Wade Was Overturned Pro-Life Ob/Gyns Say Dobbs Not End of Abortion Struggle Roe v. Wade : Medical Groups React to Supreme Court Decision February 2025: Trump Administration Announces Significant Cuts to Medical Research Funding The administration imposed a 15% cap on 'indirect costs' for NIH grants, reducing funds allocated for overhead expenses such as facilities and administrative support. But that was just one aspect of the cuts announced, reversed, or left in place, causing fear and uncertainty in the medical science community. What Happens When Science Stops Exodus of Infectious Disease Experts Imperils Public Safety Exclusive-Trump Health Layoffs Include Staff Overseeing Bird Flu Response, Source Says 2025: Measles Outbreak Response Hindered by Confusion A surge in measles cases across several states drove Medscape coverage, aiding clinicians who may have never seen a case of measles in their career while also detailing just how unprepared physicians and public health officials are for this widening crisis.
Wall Street Journal
39 minutes ago
- Wall Street Journal
Omada Health IPO to Price at $19 a Share as GLP-1s Fuel Interest
Omada Health is making its public-market debut, propelled by Americans' renewed focus on how weight affects physical health. The virtual healthcare platform on Friday will start trading publicly after 14 years of providing support to patients with weight-related chronic illnesses. Leadership sees the current moment as the perfect time for an IPO, as GLP-1 drugs such as Ozempic, Wegovy and Mounjaro have sparked renewed focus on health problems that can stem from obesity, President Wei-Li Shao said.
